Key clinical point: Combination apatinib and vinorelbine demonstrated activity in patients with wild-type, advanced non–small cell lung cancer.
Major finding: The overall response rate was 36.7% (11/30), and the disease control rate was 76.7% (23/30).
Study details: Phase 2 trial of 30 patients with wild-type, advanced non–small cell lung cancer who failed at least two prior lines of chemotherapy.
Disclosures: The study was funded by grants from the National Natural Science Foundation of China and the Hunan Natural Science Foundation. The researchers disclosed no conflicts of interest.
Zhang X et al. JAMA Netw Open. 2020;3(3):e201226. doi: 10.1001/jamanetworkopen.2020.12.